Amundi Iovance Biotherapeutics, Inc. Transaction History

Amundi

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$5.62 - $10.0 $38,109 - $67,810	-6,781 Reduced 38.28%	10,932 $69,000
Q3 2022 Nov 14, 2022	BUY	$9.53 - $13.11 $104,181 - $143,318	10,932 Added 161.22%	17,713 $175,000
Q2 2022 Aug 15, 2022	SELL	$6.38 - $18.33 $9,589 - $27,549	-1,503 Reduced 18.14%	6,781 $86,000
Q4 2021 Feb 14, 2022	BUY	$16.55 - $27.63 $11,320 - $18,898	684 Added 9.0%	8,284 $126,000
Q2 2021 Aug 16, 2021	BUY	$16.33 - $33.07 $124,107 - $251,332	7,600 New	7,600 $198,000

341

248M

4.04M

3.1M

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $879M
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

Get notified when there are updates to the investment portfolio of Amundi, based on Form 13F filings with the SEC.

Stay updated on Amundi with notifications on news.